Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. “OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, se.

Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry's first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego. OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic appli.

OmniAb to Hold OmniUltra Virtual Investor Event on December 15

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced it will hold a virtual investor event to showcase the launch of OmniUltra™ on Monday, December 15, 2025, beginning at 5:00 p.m. Eastern time. The event is expected to last approximately one hour and will include a review of OmniAb's newest technology offering, OmniUltra, the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. Management will provide an ove.

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors

EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e.